Skip to main content
. 2020 Feb 17;39(15):3041–3055. doi: 10.1038/s41388-020-1208-5

Fig. 1. Overall survival according to EGFRvIII, MGMT promoter methylation and EGFRampl. status.

Fig. 1

Kaplan–Meier estimates of EGFRvIII−/+ GBM patients treated with standard of care. a Entire cohort stratified for EGFRvIII status. b Entire cohort stratified for MGMT promoter methylation status. c MGMT-U patients stratified for EGFRvIII status. d MGMT-M patients stratified for EGFRvIII status. e EGFRampl./MGMT-M patients stratified for EGFRvIII status.